metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology
Journal Information
Issue
Vol. 20.
(January - February 2021)
STAFF
Ann Hepatol. 2021;20C:100302
Open access
Editorial
Viruses and the Liver 2020: Before COVID-19 and the beginning of a new age in medicine
Arturo Panduro
Ann Hepatol. 2021;20C:100293
Open access
Opinions
Concise reviews
A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico—A systematic review and meta-analysis (2008–2019)
Virginia Sedeño-Monge, Saul Laguna-Meraz, Gerardo Santos-López, Arturo Panduro, Francisca Sosa-Jurado, Alexis Jose-Abrego, Daniel Meléndez-Mena, Marco A. Muñoz-Ramírez, ... Sonia Roman
Ann Hepatol. 2021;20C:100292
Open access
Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis
Sahaj Rathi, Trana Hussaini, Eric M. Yoshida
Ann Hepatol. 2021;20C:211
Open access
Liquid biopsy in chronic liver disease
Hugo A. Barrera-Saldaña, Luis E. Fernández-Garza, Silvia A. Barrera-Barrera
Ann Hepatol. 2021;20C:197
Open access
Original articles
Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)
Ivan Lopez-Mendez, Jorge Aquino-Matus, Sofia Murua-Beltrán Gall, Jose D. Prieto-Nava, Eva Juarez-Hernandez, Misael Uribe, Graciela Castro-Narro
Ann Hepatol. 2021;20C:271
Open access
Open Article
LncRNA DDX11-AS1 accelerates hepatocellular carcinoma progression via the miR-195-5p/MACC1 pathway
Tao Wan, Jun Zheng, Rucheng Yao, Shuang Yang, Weihong Zheng, Pei Zhou
Ann Hepatol. 2021;20C:258
Open access
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil
Mario Peribañez-Gonzalez, Hugo Cheinquer, Lino Rodrigues, Maria Patelli Lima, Mário Reis Álvares-da-Silva, José Madruga, Edison Roberto Parise, Mário Guimarães Pessoa, ... Tania Reuter
Ann Hepatol. 2021;20C:257
Open access
Cost of illness of liver diseases in Japan
Kunichika Matsumoto, Yinghui Wu, Shigeru Fujita, Kanako Seto, Yosuke Hatakeyama, Ryo Onishi, Tomonori Hasegawa
Ann Hepatol. 2021;20C:256
Highlights

  • The COI of liver diseases in Japan has been decreasing for the past 15 years.

  • The COI of hepatitis C continued to decline despite the advent of expensive drugs.

  • The emergence of effective DAAs is expected to reduce the COI of all liver diseases.

Open access
The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies
Umar Hayat, Ali A. Siddiqui, Hayrettin Okut, Saba Afroz, Syed Tasleem, Ahmed Haris
Ann Hepatol. 2021;20C:254
Open access
Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease
José Tadeu Stefano, Laura Vilar Guedes, Arthur Alencar Arrais de Souza, Denise Siqueira Vanni, Venâncio Avancini Ferreira Alves, Flair José Carrilho, Alvaro Largura, Marco Arrese, Claudia P. Oliveira
Ann Hepatol. 2021;20C:253
Open access
Clinical evaluation of modified ALPPS procedures based on risk-reduced strategy for staged hepatectomy
Jie Li, Guang-Sheng Yang, Ke-Jian Sun, Yan Ma, Xiao-Wang Bi, Xu Han
Ann Hepatol. 2021;20C:245
Open access
PNPLA3 rs738409 associates with alcoholic liver cirrhosis but not with serum levels of IL6, IL10, IL8 or CCL2 in the Russian population
Danil I. Peregud, Valeria Yu. Baronets, Anna S. Lobacheva, Alexandr S. Ivanov, Olga S. Arisheva, Irina V. Garmash, Zhanna D. Kobalava, Sergey V. Pirozhkov, Natalia N. Terebilina
Ann Hepatol. 2021;20C:247
Open access
Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study
Zeyuan Qiang, Wenhua Zhang, Shuai Jin, Kunfu Dai, Yuting He, Lianyuan Tao, Haibo Yu
Ann Hepatol. 2021;20C:242
Open access
Salvianolic acid B blocks hepatic stellate cell activation via FGF19/FGFR4 signaling
Shuxia Tian, Min Chen, Bing Wang, Yonglong Han, Haonan Shang, Junming Chen
Ann Hepatol. 2021;20C:259
Open access
Accuracy of non-invasive methods/models for predicting esophageal varices in patients with compensated advanced chronic liver disease secondary to nonalcoholic fatty liver disease
Humberto O. Galizzi, Claudia A. Couto, Daniela O.L. Taranto, Samuel I.O. Araújo, Eduardo G. Vilela
Ann Hepatol. 2021;20C:229
Open access
Case report
Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: A case report
Samantha Thifani Alrutz Barcelos, Vincent Marin Dall’Oglio, Alexandre de Araújo, Carlos Thadeu Schmidt Cerski, Mário Reis Álvares-da-Silva
Ann Hepatol. 2021;20C:138
Open access
Preserving the organ donor pool and suprahepatic vena cava: Case series of transverse hepatectomy for polycystic liver disease
Thomas W. Smith, Ari Goldberg, Amy D. Lu
Ann Hepatol. 2021;20C:118
Open access
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos